Our Technology

ProKidney’s technology has the potential to preserve kidney function by using the patient’s own (autologous) kidney cells to potentially avoid or delay the need for dialysis. Given rilparencel is prepared from a patient’s own cells, immunosuppressive therapy is not required.

ProKidney’s innovative investigational therapy begins when tissue from a standard biopsy of the diseased kidney is sent to its manufacturing facility. ProKidney then digests the tissue from the standard biopsy and expands the patient’s kidney cells. After a selection process, selected cells are formulated into a personalized cell therapy product, which is re-injected into the patient’s damaged kidneys and assessed for whether it can restore kidney function.